Modern Technology Corp Announces Initial Markets for the 'Boveran Cancer Detection System' With $100 Million in Revenue Projected
OXFORD, Miss., Oct. 11, 2006 (PRIMEZONE) -- Modern Technology Corp (OTCBB:MODC), a diversified technology development and acquisition company, announced today the first two target markets and revenue projections for the 'Boveran Cancer Detection System' and its subsidiary for biosciences, Insight Medical Group.
The Boveran Cancer Detection System is the only system in the world that detects the single trait common to all forms of cancer. This trait is not found in any healthy cell. The system rapidly and accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test. The system is unique in the world and can be applied to any form of cell sample suspected of cancer and return a reliable test result within minutes. The system completely eliminates heretofore unreliable, subjective, and error-prone pathology diagnosis of cancer and delivers an automated and completely objective measurement of the presence or absence of cancer with the highest accuracy rate of any diagnostic technology in the world. The Boveran system is the first and only system in the world that can accurately detect and assess the chromosomal imbalance of cancer in any tissue sample. This ability allows the system to quickly and accurately identify both cancerous and non-cancerous cells.
Prostate Cancer Diagnosis
Prostate tumors with an intermediate histological grade, which represent the majority of prostate tumors that cannot be determined by current clinical laboratory methods. The measurement of chromosomal imbalance (aneuploidy) provides the only clinically useful prognostic information for patients with these intermediate grade tumors. The Boveran Cancer Detection System is the only system in the world that detects and measures this chromosomal imbalance.
There are approximately 2 million men living with prostate cancer in the U.S., with a growth rate of about 200,000 new cases per year. Based on these figures, the company projects prostate cancer diagnostics revenues of $12 million the first year for the market and over $50 million by the end of the third year.
Cervical Cancer Diagnosis
Currently, cervical cancer represents a larger market than prostate cancer with 55 million Pap smears collected in the U.S. annually. The company's first entry into this market space will be the competition-free market of 2-5 million (and rising) "ASCUS" (indeterminate) Pap smears generated annually.
Measuring aneuploidy in cervical smears is an independent predictor of biological outcome and will sort out the non-cancerous cells, precancerous cells, and cancerous cells in the ASCUS slide's cell population. There is no method at present in clinical laboratories for deciding the status of an ASCUS slide. The Boveran system can quickly deliver comprehensive and accurate results for any ASCUS slide. This puts the ASCUS market in the USA at $200-$500 million annually. The company projects cervical cancer diagnostics revenues of $16 million the first year for the market and $50 million by the end of the third year.
Overall Cancer Diagnostic Marketplace
The worldwide market potential is unquantifiable. The 'Boveran Cancer Detection System' is not limited to the cancers mentioned above. The system functions for any slide preparation and delivers rapid and accurate results in all suspected cancerous samples. It must be noted that our predictions only cover the U.S. market. The international market is much larger and will be part of the company's initial marketing efforts alongside the U.S.
The company will issue regular guidance to our shareholders keeping them informed of our developments and progress. Shareholders can expect frequent updates on our sales efforts, marketing plans, and ongoing expansion of our laboratory facilities.
About Insight Medical Group
Insight Medical Group is a specialized biosciences development company whose mission is to bring world-changing medical technology and research to market in the areas of cancer and AIDS. The Boveran Cancer Detection System was invented by Dr. David Rasnick, PhD. The technology and chromosomal imbalance theory is the result of 45 years of combined cancer research by Dr. David Rasnick, PhD and Dr. Peter Duesberg, PhD, who continues his studies on cancer research at the University of California, Berkley.
About Modern Technology Corp
Modern Technology Corp, a diversified technology development and acquisition company, builds revenues through continuous growth, strategic acquisitions and commercialization of nascent technology. MODC improves operating efficiencies through the elimination of cost redundancies and realized synergy between subsidiaries.
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.
CONTACT: Modern Technology Corp Anthony Welch (601) 213-3629
Source: PrimeZone (October 11, 2006 - 7:00 AM EST)